Acadia Pharmaceuticals 的精神分裂症候选药物 pimavanserin 在 3 期研究中未能达到主要终点，导致没有进一步的试验和库存下降。 Acadia Pharmaceuticals' schizophrenia drug candidate, pimavanserin, failed to meet primary endpoint in Phase 3 study, leading to no further trials and stock decline.

Acadia Pharmaceuticals 的精神分裂症候选药物 pimavanserin 未能达到 3 期研究的主要终点后，其股价下跌。 Acadia Pharmaceuticals' stock fell after their schizophrenia drug candidate, pimavanserin, failed to meet the primary endpoint in a Phase 3 study. 该研究旨在评估匹马范色林治疗精神分裂症阴性症状的效果，但并未证明比安慰剂有统计学上显着的改善。 The study aimed to evaluate pimavanserin for treatment of negative symptoms of schizophrenia, but did not demonstrate a statistically significant improvement over placebo. 因此，该公司宣布将不再对 pimavanserin 进行任何进一步的临床试验。 As a result, the company announced it will not conduct any further clinical trials with pimavanserin.